We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Dirui Industrial

DIRUI Industrial Co., Ltd provides laboratory equipment and clinical diagnostic reagents for the in-vitro diagnostic ... read more Featured Products: More products

Download Mobile App





DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022

By Carolyn Moody, RN - News Editor
Posted on 12 Apr 2022
Print article
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)

DIRUI Industrial Co., Ltd. (Jilin, China) presented its high-end diagnostic systems, including hematology, chemiluminescence immunoassay, chemistry and urinanalysis analyzers, for hospitals and high-volume labs at EUROMEDLAB 2022.

DIRUI demonstrated its BF-7200Plus automatic hematology analysis system which has a maximum throughput of 480 tests per hour and measures 37 parameters (including RET detection), five scattergrams and two histograms. It performs optical analysis for WBC measurement and comes with pathology and morphology abnormality alarms. DIRUI also demonstrated its new CM180 chemiluminescence immunoassay analyzer with a throughput of up to 180 tests/hour and walk-away time of up to 2.5 hours. The CM180 has time to first result of only 15 minutes and allows 25 items to be tested at the same time. Featuring a user-friendly design to keep test results accurate and reliable, the CM180 analyzer provides the best solution for laboratory chemiluminescence immunoassay.

Also on display at EUROMEDLAB 2022 was DIRUI’s CS-T240Plus automatic chemistry analyzer which offers the ultimate in convenience, performance and confidence for small to medium size laboratories. The powerful desktop analyzer has a maximum throughput of 240 tests/hour at constant speed and 480 tests/hour for ISE. It uses whole blood samples to test for HbA1c, ensuring more accurate results and has a water consumption of only three liters per hour. This automated random access clinical chemistry analyzer can be easily integrated with any type of laboratories for routine, emergency analysis. In addition, DIRUI showcased its MUS-3600 automatic urinanalysis system with a flexible combination of modules and super fast detection speed. It has a throughput of up to 480 tests per hour (for hybrid) and allows up to 580 urine samples to be loaded at one time. Using leading detection methodologies, the MUS-3600 can provide objective and quantitative report information, clear and visible particle image information, and three key clinical information - red blood cell morphology information, urinary tract infection information, and urine culture information.

Related Links:
DIRUI Industrial Co., Ltd. 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.